Mk2866 OTR-AC

OTR-AC is a selective androgen receptor modulator (SARM) that is also commonly referred to as Ostarine-O-Acetate. This compound is an esterified version of the popular SARM, Ostarine, or MK-2866. While Ostarine and OTR-AC elicit similar benefits, the latter is considered to be the stronger of the two compounds following the esterification process.
Due to its ability to bind to androgen receptors, the SARM has been shown to mimic the action of testosterone. SARMs are becoming more popular and widely available for research purposes as evidence shows the compounds do not elicit negative androgenic side effects, like those observed with testosterone treatment.

Main Research Findings
1) The process of esterification leads to increased potency and improved efficacy of OTR-AC in comparison to its parent compound, MK-2866.
2) SARMs have been shown to promote various forms of functional therapy through tissue-selective activation of androgenic signaling
3) Ostarine has the potential to induce myogenic differentiation in the muscles of animal test subjects, as well as in C2C12 and L6 cells.